All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

TriSalus Life Sciences Q3 revenue misses estimates

By Reuters News


Overview

  • US oncology medtech firm's Q3 revenue rose 11% yr/yr but missed analyst expectations

  • Company narrowed operating and adjusted EBITDA losses, helped by improved gross margins and lower R&D costs

  • 2026 revenue guidance revised to $46 mln-$48 mln, implying 2%-6% growth over 2025


Outlook

  • TriSalus revises 2026 revenue guidance to $46 mln-$48 mln, up 2%-6% year over year

  • Company expects continued growth in 2027, citing expanded commercial footprint and new product launches

  • CMS finalizes expanded reimbursement for PEDD procedures, effective January 2027


Result Drivers

  • TRINAV SALES - Co said Q3 revenue growth was mainly driven by higher TriNav system sales

  • LOWER UNIT COSTS - Co attributed improved gross margins to reduced cost per TriNav unit

  • COMMERCIAL EXPANSION - Co expanded its commercial organization, though team productivity ramped slower than expected


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$12.88 mln

$14.02 mln (5 Analysts)

Q3 Loss Per Share

$0.15

Q3 Gross Profit

$11.10 mln

Q3 Income from Operations

-$7.71 mln

Q3 Pretax Loss

$8.85 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for TriSalus Life Sciences Inc is $9.00, about 179.5% above its November 9 closing price of $3.22


Reuters Recommended Reads

  • Nov 9 - Oncology firm Delcath Systems' Q3 revenue beats on Hepzato growth

  • Nov 9 - Abeona Therapeutics Q3 profit beats expectations on treatment network expansion

  • Nov 9 - Medical tech firm NeurAxis' Q3 revenue jumps on broader insurance coverage


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.